Previous close | 22.80 |
Open | 0.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 221 |
Market cap | 16.577M |
Beta (5Y monthly) | 1.84 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.11 |
Earnings date | 02 Aug 2023 - 07 Aug 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The main aim of stock picking is to find the market-beating stocks. But in any portfolio, there will be mixed results...
Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test.
Investing.com -- Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: an Outperform initiation at Zions Bancorp and upgrades at KeyCorp, Greenhill, and Myriad Genetics.
Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.
Myriad Genetics ( NASDAQ:MYGN ) First Quarter 2023 Results Key Financial Results Revenue: US$181.2m (up 9.9% from 1Q...
Myriad Genetics (MYGN) delivers a year-over-year increase in first-quarter revenues, reflecting a positive volume improvement across the portfolio.
Myriad (MYGN) delivered earnings and revenue surprises of -10.53% and 5.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) and Intermountain Precision Genomics receive the New York State Clinical Laboratory Permit to offer solid tumor testing to patients in all 50 U.S. states.
Myriad Genetics' (MYGN) latest program will increase access to affordable genetic testing. It will also aid in identifying and elevating high-risk patient care.
Myriad Genetics (MYGN), together with Illumina, will seek joint HRD companion diagnostics partnerships with pharmaceutical companies globally.
Key Insights Using the 2 Stage Free Cash Flow to Equity, Myriad Genetics fair value estimate is US$19.13 With US$22.90...
Myriad Genetics (MYGN) hereditary cancer testing volume registered strong growth in the fourth quarter. GeneSight comes up with yet another strong performance.
Myriad (MYGN) delivered earnings and revenue surprises of 25% and 5.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics' (MYGN) significant gross margin contraction and operating loss as a result of mounting cost pressure are concerning.
Statistically speaking, long term investing is a profitable endeavour. But along the way some stocks are going to...
Myriad Genetics' (MYGN) latest launch is expected to aid clinicians with access to tools that can assist them with turnaround times and report interpretation.
What happened Shares of Myriad Genetics (NASDAQ: MYGN), a genetic-testing and precision-medicine biotech company, were down more than 24% this week as of Thursday, according to data from S&P Global Intelligence.
Myriad Genetics (MYGN) hereditary cancer testing volume returns to growth in the third quarter. GeneSight comes up with yet another strong performance.
Myriad (MYGN) delivered earnings and revenue surprises of -375% and 9.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myriad Genetics' (MYGN) expansion across the globe, banking on myChoiceCDx test sales, seems impressive.
Myriad Genetics' (MYGN) BRACAnalysis gained expanded coverage from MHLW to identify breast cancer patients who are eligible for treatment with Lynparza in Japan.
Investing in biotech stocks can be a leap of faith. Many of those in the sector with the most promising therapies aren't profitable, and some have taken a drubbing so far this year. If you're investing for the long term, however, biotech companies can provide huge potential.
Investors are optimistic about Myriad Genetics' (MYGN) better-than-expected results and strong testing volumes.
How far off is Myriad Genetics, Inc. ( NASDAQ:MYGN ) from its intrinsic value? Using the most recent financial data...